Nanjing Enrui Kainuo Biotechnology Co., Ltd, a China-based cell therapy developer, has reportedly raised tens of millions of renminbi in a pre-Series A financing round. The round was led by Watere Capital, with participation from Future Invest. The funds raised will be directed towards IND filings, advancing the product pipeline, investigator-initiated trials (ITTs), and early-stage research and development.
Enrui Kainuo Bio’s Innovative Platforms and Pipeline
Founded in 2021, Enrui Kainuo Bio boasts a robust portfolio of platforms, including a CAR-NK platform, a single base gene editing platform, and an IPSC platform for small molecule induced differentiation. These technologies position the company at the forefront of cell therapy innovation.
Diverse Product Pipeline
The company’s product pipelines span a range of therapeutic areas, including oncology, autoimmune diseases, central nervous system (CNS) diseases, and anti-aging products. This diversity underscores Enrui Kainuo Bio’s commitment to addressing significant unmet medical needs and its potential to impact various aspects of healthcare.-Fineline Info & Tech
